Insights into a new therapy for a rare form of cystic fibrosis

Scientists at the Hospital for Sick Children in Toronto have established that a drug recently approved by the U.S. Food and Drug Administration to treat a rare form of cystic fibrosis works in an unconventional way. Their results reveal new possibilities for treating various forms of cystic fibrosis.

is an inherited disease afflicting about 70,000 people around the world. Cystic fibrosis patients carry a that disables or destroys its protein product, which normally regulates the transport of ions across cell borders. When that transport is disrupted, the viscosity of the mucus coating certain organs becomes too thick. A characteristic feature of the disease is buildup in the air passages, which causes difficulty breathing and recurring infections.

While the FDA approved the drug VX-770 (also known by the trade names Kalydeco and Ivacaftor) to ease breathing in people with cystic fibrosis caused by a particular mutation in the (the acronym is short for cystic fibrosis transmembrane conductance regulator), exactly how VX-770 worked in those patients was unknown.

Scientists have understood for some time that normal CFTR regulation requires modification of the protein and binding of a small, energy-providing molecule – adenosine triphosphate, or ATP. But, in their recent "Paper of the Week," Christine Bear and colleagues report that the drug opens both normal and mutant CFTR channels without ATP. Their results indicate that the compound binds to a different site on CTFR than ATP. Significantly, this finding may be useful in developing therapies for cystic fibrosis caused by various CFTR mutations that, like the G551D mutation that was studied, impair ATP-mediated channel regulation.

Bear's group determined how VX-770 works after developing a new experimental system that may have potential for discovering drugs that target the basic defects caused by CFTR mutations, Bear says. The system is useful for identifying compounds that interact with rare such as G551D as well as the major CFTR mutant F508del, she said.

add to favorites email to friend print save as pdf

Related Stories

An 'unconventional' path to correcting cystic fibrosis

Sep 01, 2011

Researchers have identified an unconventional path that may correct the defect underlying cystic fibrosis, according to a report in the September 2nd issue of the journal Cell. This new treatment dramatically extends the li ...

Recommended for you

New device to monitor lung function in space

39 seconds ago

A new method of collecting blood from the ear, currently part of an interactive exhibition at the Science Museum, could be used to monitor lung function in space. Less invasive, faster and more accurate than current methods, ...

Primate research center plays key role in HIV study in Nature

3 minutes ago

In a study reported in Nature this month, Yerkes National Primate Research Center researchers were key in determining that treating SIV-infected rhesus macaques with type 1 interferon, a protein known to trigger antiviral respon ...

Three-people IVF debate process on the move in UK

2 hours ago

Takes two to make a child, correct? No. maybe. The use of sperm and eggs from three people to create babies moved a step closer in the UK, with Tuesday's events. What kind of egg-sperm distribution are we talking about? The ...

User comments